Cardiothoracic Surgery

The Department of Cardiothoracic Surgery is a recognized leader in heart, lung and esophagus surgery. Our experience with complex cardiothoracic issues and knowledge of the latest advances have helped to establish NewYork-Presbyterian|Weill Cornell Medicine as a major referral center for cardiovascular and thoracic patients from around the world.

Cardiac Surgery

The Division of Cardiac Surgery provides expert care to patients who need:

  • Coronary artery bypass surgery
  • Valve repair/replacement
  • Surgery for adult congenital heart disease
  • Minimally Invasive Heart Surgery
  • Ventricular Assist Devices (VADs)
Learn More
Cardiac Surgery team

Thoracic Surgery

The Division of Thoracic Surgery offers the most advanced surgical care for:

  • Lung and esophageal cancers
  • Emphysema
  • Hyperhidrosis
  • Hiatal hernia
  • Pericardial & Pleural Effusions
  • Thoracentesis
Learn More
Thoracic Surgery team

Why Choose Weill Cornell?

New Advances

Dr. Leonard N. Girardi

Appointed to the NY State Cardiac Advisory Committee - November 2016

Appointed to the National Marfan Foundation Professional Advisory Board - December 2016

Dr. Brendon Stiles

Served as chairman of a panel for the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP), Lung Cancer Research Program - November 2016

Patients Recover Faster After Robotic Heart Surgery

By Dana Arschin
December 15

Dr. T. Sloane Guy appears on FOX 5 to discuss the benefits of using robotics for heart surgery and highlights a patient who had a successful outcome. Dr. Guy does about 100 robotic heart surgeries a year and his goal is to more than double that number. He said the problem is that not enough patients know that this type of surgery exists and next spring he will be organizing a training for doctors across the country.
Dr. T. Sloane Guy, associate professor of clinical cardiothoracic surgery

Understanding Crosstalk in Tumor Microenvironment Could Lead to New Precision Medicine Approaches

Many patients with non-small cell lung cancer (NSCLC) have no identifiable mutations, and therefore their disease cannot be managed with targeted treatments. These patients often experience disease progression despite chemotherapy. However, a study led by investigators at Weill Cornell Medical Medicine used a new approach to examine crosstalk between cancer cells and cells in the microenvironment in NSCLC. Instead of looking at the tumor as a whole, the researchers used deep sequencing of RNA to analyze individual cell populations isolated from NSCLC specimens, an approach that could someday lead to new treatments for patients with NSCLC. 

Clinical Trials

The Cardiothoracic Surgery Department conducts a robust clinical trials program to evaluate the effectiveness of new treatments and medications that have the potential to improve the management of patients with heart, lung, and esophageal disease. The outcomes of heart, lung, and esophageal operations can be improved with technical innovations.

Current Clinical Trials

 

US World News Ranking logo

The Weill Cornell Medicine's Department of Cardiothoracic Surgery is proud to partner with NewYork-Presbyterian, ranked #6 in the nation and #1 in NYC by U.S. News and World Report.